European Journal of Pediatrics

, Volume 134, Issue 1, pp 57–63 | Cite as

Peritoneal dialysis in maple-syrup-urine disease: Studies on branched-chain amino and keto acids

  • U. Wendel
  • K. Becker
  • Hildegard Przyrembel
  • Monika Bulla
  • C. Manegold
  • Angelika Mench-Hoinowski
  • U. Langenbeck
Original Investigations


We report biochemical data on a child with MSUD who underwent peritoneal dialysis for severe metabolic imbalance. In confirmation of earlier data, the BCKA/BCAA ratios in blood had been found to be fairly stable in this patient during long-term dietary therapy.

The child became comatose at comparatively low levels of leucine and KICA (ca. 2 mM each). At this time the blood/cerebrospinal fluid ratio for BCAA's and BCKA's was markedly diminished. During peritoneal dialysis, peritoneal clearance was highest for KIVA, but less for MEVA and BCAA's (40–50% or urea clearance), and least for the allegedly most toxic metabolite, KICA. The differences for BCKA's may be due to their differential protein binding. Given these individual differences, 1.8 to 8.7 initial plasma volumes were cleared in 14h with 24.21 of dialysis fluid. In the same time, urinary excretion of BCAA's and BCKA's was much less efficient.

The data are discussed with regard to the pathobiochemical significance of high tissue levels of branched chain acids. A quantitative comparison between peritoneal dialysis and exchange transfusion is not yet possible.

Key words

Maple syrup urine disease Peritoneal dialysis Peritoneal clearances Branched-chain α-amino acids Branched-chain α-keto acids 



branched-chain α-amino acids


branched-chain α-keto acids


α-keto-isocaproic acid


α-keto-isovalerio acid


α-keto-β-methyl-n-valeric acid


maple syrup urine disease


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Astine, J., Froye, E., Luciani, J.-M., Bellet, H., de Bornier, P. M., Brunel, D.: Leucinose néo-natale d'évolution favorable. Problèmes évolutives et thérapeutiques. Ann. Pédiat. 24, 605–610 (1977)Google Scholar
  2. 2.
    Benson, J. V., Cormick, J., Patterson, J. A.: Accelerated chromatography of aminoacids associated with phenylketonuria, leucinosis (maple syrup urine disease) and other inborn errors of metabolism. Anal. Biochem. 18, 481–492 (1967)Google Scholar
  3. 3.
    Boen, S. T.: Peritoneal dialysis in clinical medicine. Springfield, Ill.: Thomas 1964Google Scholar
  4. 4.
    Bulla, M.: Dialyse im Kindesalter. Stuttgart: Enke 1977Google Scholar
  5. 5.
    Dancis, J., Hutzler, J., Lewitz, M.: Metabolism of the white blood cells in maple syrup urine disease. Biochim. Biophys. Acta 43, 342–343 (1960)Google Scholar
  6. 6.
    Dent, C. E., Westall, R. G.: Studies in maple syrup urine disease. Arch. Dis. Child. 36, 259–268 (1961)Google Scholar
  7. 7.
    Dreyfus, P. M., Prensky, A. L.: Further observations on the biochemical lesion in maple syrup urine disease. Nature 214, 276 (1967)Google Scholar
  8. 8.
    Gaull, G. E.: Pathogenesis of maple syrup urine disease: Observation during dietary management and treatment of coma by peritoneal dialysis. Biochem. Med. 3, 130–149 (1969)Google Scholar
  9. 9.
    Gaull, G. E., Tallan, H. H., Lajtha, A., Rassin, D. K.: Pathogenesis of brain dysfunction in inborn errors of amino acid metabolism. In: Biology of brain dysfunction, Vol. 3, G. E. Gaull (ed.). New York, London: Plenum 1975Google Scholar
  10. 10.
    Hammersen, G., Wille, L., Schmidt, H., Lutz, P., Bickel, H.: Maple syrup urine disease: Treatment of the acutely ill newborn. Eur. J. Pediatr. 129, 157–165 (1978)Google Scholar
  11. 11.
    Harris, R. J.: Infection in maple-syrup urine disease. Lancet 1971 II, 813–814Google Scholar
  12. 12.
    Humoller, F. L., Mahler, D. J., Parker, M. M.: Distribution of amino acids between plasma and spinal fluid. Int. J. Neuropsych. 2, 293–297 (1966)Google Scholar
  13. 13.
    Lancaster, G., Mamer, O. A., Scriver, C. R.: Branched-chain alpha-keto acids isolated as oxime derivatives: Relationship to the corresponding hydroxy acids and amino acids in maple syrup urine disease. Metabolism 23, 257–265 (1974)Google Scholar
  14. 14.
    Langenbeck, U., Hoinowski, A., Mantel, K., Mehring, H.-U.: Quantitative gaschromatography and single-ion detection of aliphatic α-keto acids from urine as their o-trimethylsilyl quinoxalinol derivatives. J. Chromatogr. 143, 39–50 (1977)Google Scholar
  15. 15.
    Langenbeck, U., Matthaei, D.: Unpublished observations, 1979Google Scholar
  16. 16.
    Langenbeck, U., Wendel, U., Luthe, H.: Renal clearance of branched-chain 2-oxo-acids in maple syrup urine disease. J. Clin. Chem. Clin. Biochem. 17, 176–177 (1979)Google Scholar
  17. 17.
    Langenbeck, U., Wendel, U., Mench-Hoinowski, A., Kuschel, D., Becker, K., Przyrembel, H., Bremer, H. J.: Correlations between branched-chain amino acids and branched-chain α-keto acids in blood in maple syrup urine disease. Clin. Chim. Acta 88, 283–291 (1978)Google Scholar
  18. 18.
    Rapoport, S. J.: Blood-brain barrier in physiology and medicine. New York: Raven Press 1976Google Scholar
  19. 19.
    Rey, F., Rey, J., Cloup, M., Féron, J.-F., Doré, F., Labrune, B., Frézal, J.: Traitement d'urgence d'une forme aigue de leucinose par dialyse peritoneale. Arch. Franç. Pédiat. 26, 133–137 (1969)Google Scholar
  20. 20.
    Sallan, S. E., Cottom, D.: Peritoneal dialysis in maple syrup urine disease. Lancet 1969 II, 1423–1424Google Scholar
  21. 21.
    Saudubray, J.-M., Fournet, J.-P., Cloup, M.: Intérêt de la dialyse péritonéale dans le traitement d'urgence des maladies métaboliques d'origine constitutionelle révélées dans la période néo-natale. Ann. Méd. interne 122, 1279–1283 (1971)Google Scholar
  22. 22.
    Schauder, P., Matthaei, D., Scheler, F., Mench-Hoinowski, A., Langenbeck, U.: Blood levels of branched-chain α-keto acids in uremia: therapeutic implication. Klin. Wochenschr. 57, 825–830 (1979)Google Scholar
  23. 23.
    Schuchmann, L., Witt, I., Schulz, P., Schuhmacher, H., Rüdiger, H. W.: Multiple exchange transfusions as treatment during the acute period in maple syrup urine disease. Helv. Paediat. Acta 27, 449–456 (1972)Google Scholar
  24. 24.
    Scriver, C. R., Rosenberg, L. E.: Amino acid metabolism and its disorders, pp. 54–56. Philadelphia: Saunders 1973Google Scholar
  25. 25.
    Snyderman, S. E., Norton, P. M., Roitman, E., Holt, L. E., Jr.: Maple syrup urine disease with particular reference to dieto-therapy. Pediatrics 34, 454–472 (1964)Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • U. Wendel
    • 1
  • K. Becker
    • 1
  • Hildegard Przyrembel
    • 1
  • Monika Bulla
    • 2
  • C. Manegold
    • 2
  • Angelika Mench-Hoinowski
    • 3
  • U. Langenbeck
    • 3
  1. 1.University Children's Hospital CDüsseldorfFederal Republic of Germany
  2. 2.University Children's HospitalKölnFederal Republic of Germany
  3. 3.Institute of Human GeneticsUniversity of GöttingenGöttingenFederal Republic of Germany

Personalised recommendations